Radical Collaboration: IBM Microelectronics Joint Development Alliances

Willy  Shih; Gary  Pisano; Andrew A. King

Case | HBS Case Collection | February 2008 (Revised November 2008)

Radical Collaboration: IBM Microelectronics Joint Development Alliances

by Willy Shih, Gary Pisano and Andrew A. King

Abstract

IBM's "Radical Collaboration" model has been an innovative approach to meeting the challenges of the huge R&D and capital investments that are needed to stay competitive in the global semiconductor industry. This model has required a rethinking of what is proprietary, and what is shared, and where do the boundaries of cooperation end and competition begin. IBM and its partners have managed to stay competitive at, for example, the 45 nm node, at a far lower cost than firms that "go it alone," and there is a large benefit from a larger funnel of ideas and diverse points of view. It also reshapes what firms can use to build competitive advantage, or it necessitates a rethinking at least.

Keywords: Cost Management; Investment; Collaborative Innovation and Invention; Problems and Challenges; Alliances; Networks; Partners and Partnerships; Research and Development; Competitive Advantage; Semiconductor Industry;

Format: Print

21 pages

Educators Purchase

Citation:

Shih, Willy, Gary Pisano, and Andrew A. King. "Radical Collaboration: IBM Microelectronics Joint Development Alliances." Harvard Business School Case 608-121, February 2008. (Revised November 2008.)

This case examines four Special Economic Zones in Myanmar. While the country's development had been hobbled by a complex history of military rule, ethnic conflict, and international sanctions, as it pursued liberalization it sought avenues to developing its economy. The four zones described in the case – Dawei, Kyaukphyu, Thilawa, and the New Yangon City project all had different roots and different motivations. The different rates of progress of each reflected the interests and approaches of each of the projects' participants.

Vaccines for children has been a long-standing focus for the Bill & Melinda Gates Foundation, and their critical role in public health made their production an important economic and political issue. This case describes the Foundation's investment in a breakthrough vaccine manufacturing platform for the Sabin inactivated polio virus. While the new technology promised a much lower cost per dose, it also raised questions about the consequences of lowering entry barriers to vaccine production, as maintaining high quality and production standards, a strong regulatory environmen were critical to protecting the integrity of the vaccine supply. The new technology also threatened to encourage more developed country vaccine manufacturers to exit the market, not an outcome the Foundation was hoping for, as they possessed the capabilities and resources to invest in future developments. It raises the question of whether vaccines are a public good, and who should be responsible for their production.

Faculty & Research

Radical Collaboration: IBM Microelectronics Joint Development Alliances

Abstract

Citation:

About the Authors

More from these Authors